$22.12
0.41% today
Nasdaq, Apr 01, 07:18 pm CET
ISIN
BMG5269C1010
Symbol
KNSA
Sector
Industry

Kiniksa Pharmaceuticals Ltd. Class A Stock price

$22.21
+1.93 9.52% 1M
-2.78 11.12% 6M
+2.43 12.29% YTD
+2.51 12.74% 1Y
+12.27 123.44% 3Y
+6.73 43.48% 5Y
+2.74 14.07% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.88 3.81%
ISIN
BMG5269C1010
Symbol
KNSA
Sector
Industry

Key metrics

Market capitalization $1.61b
Enterprise Value $1.38b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 54.30
EV/Sales (TTM) EV/Sales 3.26
P/S ratio (TTM) P/S ratio 3.81
P/B ratio (TTM) P/B ratio 3.67
Revenue growth (TTM) Revenue growth 56.60%
Revenue (TTM) Revenue $423.24m
EBIT (operating result TTM) EBIT $-45.62m
Free Cash Flow (TTM) Free Cash Flow $25.41m
Cash position $243.63m
EPS (TTM) EPS $-0.61
P/E forward 39.90
P/S forward 2.76
EV/Sales forward 2.36
Short interest 9.38%
Show more

Is Kiniksa Pharmaceuticals Ltd. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Kiniksa Pharmaceuticals Ltd. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

Buy
100%

Financial data from Kiniksa Pharmaceuticals Ltd. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
423 423
57% 57%
100%
- Direct Costs 190 190
103% 103%
45%
234 234
32% 32%
55%
- Selling and Administrative Expenses 166 166
34% 34%
39%
- Research and Development Expense 111 111
48% 48%
26%
-44 -44
102% 102%
-10%
- Depreciation and Amortization 1.70 1.70
50% 50%
0%
EBIT (Operating Income) EBIT -46 -46
81% 81%
-11%
Net Profit -43 -43
407% 407%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Kiniksa Pharmaceuticals Ltd. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiniksa Pharmaceuticals Ltd. Class A Stock News

Positive
The Motley Fool
18 days ago
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.
Neutral
Seeking Alpha
about one month ago
Big Pipeline Updates From Kiniksa Pharmaceuticals
Neutral
Seeking Alpha
about one month ago
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript
More Kiniksa Pharmaceuticals Ltd. Class A News

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Sanj Patel
Employees 315
Founded 2015
Website www.kiniksa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today